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Purpose: Nitric oxide (NO) not only relaxes vascular smooth muscles, but it also reduces 
platelet adhesion and is itself a potent antiaggregatory substance. Experimental studies \ 
have shown thar the release of NO is modulated by the blood flow. However, little 
clinical information is available about the effects of hemodynamic changes after a terial 
reconstruction  NO production. We therefore xamined whether the plasma levels of 
nitrite (NO2-) and ~itrate (NOa-) ions increased after arterial reconstruction in patients 
with arteriosclerosis obliterans (ASO). 
Methods: Blood samples were obtained from the femoral artery in seven patients who 
underwent arterial reconstruction and seven healthy individuals (control). NO2- and 
NO 3- levels were measured using high-performance liquid chromatography before the 
operation and I hour and 14 days after the operation. In addition, the mean femoral 
artery blood flow and ankle-brachial pressure index (ABI) were also measured using a 
duplex and Doppler velocimeter both before and after the operations. 
Results: In the control subjects, the mean plasma NO2- , NOa- , and NO x (NO Z plus 
NOz- ) levels in the femoral artery were 0.37 +-. 0.15 ~mol/L, 45.6 --. 10.8 I~mol/L, and 
46.0 - 10.9 ~mol/L, respectively. Before the operation in the patients with ASO, the 
mean plasma NO 3- (23.8 --- 2.2 I~mol/L) and NO x levels (24.0 - 2.3 Ilmol/L) were 
significantly lower than those in the control subjects, whereas the plasma NO2- levels 
(0.27 __. 0.04 ~mol/L) were comparable between the two groups. At 14 days after 
operation, the mean plasma NOz- and NO x levels in the femoral artery were significantly 
increased to 42.8 __. 5.6 ~mol/L and 43.4 - 5.6 I~mol/L compared with those before the 
operation, whereas the mean plasma NO 2- levels (0.50 --- 0.05 I~mol/L) changed 
significantly. The mean ABI and the mean flow rate before the operation were 0.32 --- 
0.07 and 344 + 145 ml/min, respectively. Both the ABI and the mean flow rate 
significantly increased to 1.04 +- 0.06 and 627 - 141 ml/min after the operation. 
Conclusions: In patients who have ASO, the mean plasma level of NO is significantly 
lower than that of healthy individuals. In patients with ASO, the mean blood flow 
increased significantly after arterial reconstruction. This hemodynamic improvement may 
thus enhance NO production and may also help to maintain the patency of the bypass 
graft or native artery. (J Vasc Surg 1997;26:657-62.) 
The endothelium odulates the underlying vas- 
cular smooth muscle by releasing a potent vasodila- 
tor, endothelium-derived relaxing factor (EDRF), 1 
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which has been identified as nitric oxide (NO). 2 NO 
not only relaxes vascular smooth muscle, but it also 
reduces platelet adhesion and is itselfa potent antiag- 
gregatory substance. 3 s It is well known that the 
biologic activity of  endothelium-derived NO is im- 
paired both in patients with athcroscrerosis 6-  and in 
atherosclerotic animal models. 6,9,~° However, little 
information is available on NO production in pa- 
tients who have arteriosclerosis obliterans (ASO). 
Chronic elevations in the blood flow result in 
increased endothelium-dependent relaxations, n-13 
We recently demonstrated that endothelium-depen- 
dent relaxation caused by adenosine diphosphatc was 
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Table I. Clinical characteristics of patients with ASO 
ABI 
Patient Sex Age (yr) Operation Before operation After operation Cholesterol (mg/dl) Tr~lyceride (mg/dl) 
1 M 70 A-F 0.32 1.08 
2 M 69 A-F 0.28 1.08 
3 M 73 A-I 0.46 1.08 
4 M 66 A-F 0.27 1.02 
5 M 73 A-F 0.27 0.95 
6 M 76 A-F 0.30 1.10 
7 M 68 A-F 0.34 0.98 
207 
198 
184 
234 
180 
210 
196 
82 
108 
77 
90 
114 
80 
100 
ABI, Aalkle-brachial index; A-F, aortofemoral bypass; A-/, aortoiliac bypass. 
impaired as a result of poor runoff conditions in the 
canine femoral arteries. 14 The production of 
EDRF-NO is thus considered to be modulated by 
alterations in the blood flow. Despite these experi- 
mental results, there is no direct evidence for the 
modulation of the NO production with hemody- 
namic changes after arterial reconstruction in human 
blood vessels. 
NO is supposed to be degraded into nitrite 
(NO2-) and nitrate (NO3-) ions. 15 In the present 
study, we examined whether the plasma levels of 
nitrite (NO2-) and nitrate (NO3-) ions are de- 
creased in patients with ASO compared with healthy 
human beings and, if so, whether the plasma levels of  
nitrite (NO2-) and nitrate (NO3-) ions increased 
after arterial reconstruction in patients with ASO. 
MATERIALS AND METHODS 
This study was conducted with seven patients 
with ASO (Table I), as well as with the seven healthy 
individuals (control) without ASO. All of the pa- 
tients had intermittent clandication before undergo- 
ing the operation. The average age of the patients 
was 70.7 -+ 3.5 years, with a range of 66 to 76 years. 
Six patients who had occlusion of the common and 
external i iac arteries underwent an aortofemoral r- 
tery bypass procedure, whereas one patient had an 
occlusion of the common iliac artery and underwent 
an aortoiliac artery bypass procedure. 
In the seven healthy individuals (control), the 
average age was 69.6 + 4.4 years, with a range of 63 
to 79 years. They had no intermittent claudication, 
and the pulse of the peripheral rtery was good. This 
study was approved by the Kyushu University Insti- 
tutional Review Board. 
Measurements of nitrite (NO2-) and nitrate 
(NOa-) ions. NO 2- and NO 3- were measured by 
high-performance liquid chromatography-Diazoti- 
zation detection method 16 (Eicom NOx Analysis 
System, Model ENO-10, Kyoto, Japan) before oper- 
ation, as well as 1 hour and 14 days after the opera- 
tion. Samples before operation and 14 days after 
operation were taken before breakfast. 
The arterial blood samples (10 ml each) were 
drawn from the femoral artery and were immediately 
centrifuged for 5 minutes at 2500g. The serum was 
separated and frozen at -70 ° C for subsequent high 
performance liquid chromatography. 
NO 2- and NO 3- in the plasma were separated by 
a reverse-phase separation column packed with poly- 
styrene polymer (NO-PAK, 4.6 × 50 mm, Eicom), 
and NO 3 was reduced to NO 2- in a reduction 
column packed with copper-plated cadmium filings 
(NO-RED, Eicom). NO 2- was mixed with a Griess 
reagent to form a purple azo dye in a reaction coil. 
The separation and reduction column and the reac- 
tion coil were placed in a column that was set at 
35 ° C. The absorbance of the color of the product 
dye at 540 nm was measured by flow-through spec- 
trophotometer (NOD-10, Eicom). The mobile 
phase, which was delivered by a pump at a rate of 
0.33 ml/min, was 10% methanol containing 0.15 
mol/L NaC1/NH4CL and 0.5 g /L  4Na-ethyl- 
enediamine tetraacetic acid. The Griess reagent, 
which was 1.25% HC1 containing 5 g /L  sulfanil- 
amide with 0.25 g /L  N-naphthylethylenediamide, 
was delivered at a rate of 0.1 ml/min. The amount of 
NO 2- and NO 3- contained inRinger's olution and 
the reliability of the reduction column were exam- 
ined in each experiment. The calibration curve was 
obtained using 1 ~mol/L and 10 Ixmol/L NaNO 2 
and NaNO a. 
Doppler-derived systolic pressure measure- 
ments. The resting ankle systolic pressure was mea- 
sured before and 14 days after the operation with the 
transcutaneous Doppler ultrasonographic flow de- 
tection technique. The anklc-brachial index was cal- 
culated by dividing the ankle systolic pressure by the 
brachial systolic pressure using the same technique. 
Mean flow measurements by Duplex scan. 
The patients were all examined in the supine posi- 
tion. The mean blood flow of the common femoral 
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Table II. Plasma levels o f  NO2- , NO 3- and NO x 
NO 2- (~mol/L) NO 3- (p~mol/L) NO x Oxmol/L) 
A B C A B C A B C 
1 0.34 0.35 0.47 17.0 16.4 28.7 17.3 16.8 29.2 
2 0.18 0.18 0.51 16 .7  15.5 28.1 16.9 15.8 28.6 
3 0.28 0.30 0.76 24.8 20.8 66.0 25.1 21.1 66.8 
4 0.45 0.38 0.56 31.0 28.0 59.6 31.5 28.4 60.2 
5 0.30 0.32 0.50 26.8 25.0 42.3 27.1 25.4 42.8 
6 0.22 0.27 0.40 20.1 18.7 35.2 20.3 19.0 35.6 
7 0.13 0.20 0.30 30.0 19.1 40.0 30.1 19.3 40.3 
A, Before operation; B, 1 hour after arterial reconstruction; C, 14 days after operation. 
artery was measured by duplex scan before and 14 
days after the operation. A duplex system with a 
probe 3.75 MHz pulsed Doppler flow detector 
(Toshiba SSA-270A, Tokyo) was used? 7 
Calculations and statistical analysis. The re- 
sults are expressed as the mean + SEM. A statistical 
evaluation of the data was performed by an analysis 
of  variance. If  the value was statistically significant, 
then post hoc tests for multiple comparisons (Fisch- 
er's protected least significant difference) were used 
to identify differences among the groups. The values 
were considered to be statistically significant when 
the p value was less than 0.05. 
RESULTS 
The average serum cholesterol and triglyceride 
levels in patients with ASO were 201.3 + 18.1 
mg/d l  and 93.0 + 14.5 mg/dl ,  respectively. The 
average serum cholesterol and triglyceride levels in 
control subjects who did not have ASO were 
193.3 + 31.8 mg/d l  and 86.0 + 19.9 mg/dl ,  re- 
spectively. In addition, no statistical significance was 
seen between the two groups. None of the patients 
had hypercholesterolemia. 
Arterial reconstruction significantly increased the 
ankle-brachial index from 0.32 + 0.03 before opera- 
tion to 1.04 + 0.02 after arterial reconstruction. 
In the control group, the mean flow rate in the 
femoral artery was 541 + 50 ml/min. In the pa- 
tients, the mean flow rate (344 + 55 ml/min) before 
the operation was significantly lower than that of the 
control group. Arterial reconstruction significantly 
increased the mean flow rate to 627 + 53 ml/min at 
14 days after surgery, which was comparable with 
that of the control group. 
In the control subjects, the plasma NO2- , NO3- , 
and NO x (NO 2- plus NO 3 ) levels in the femoral 
artery were 0.37 + 0.15 ~tmol/L, 45.6 + 10.8 
/xmol/L, and 46.0 + 10.9 ~tmol/L, respectively. 
Before the operation in the patients with ASO, 
plasma NO2- , NO3- , and NO x levels in the femoral 
artery were 0.27 -- 0.04 txmol/L, 2318 _ 2.2 Ixmol/L 
and 24.0 +_ 2.3 Ixmol/L, respectively. The NO 3- and 
NO x levels in the control subjects were significantly 
higher than those of the patients with ASO (Table II). 
At 1 hour after arterial reconstruction, the plasma 
NO2- , NO3- , and NO x levels in the femoral artery 
were 0.29 +_ 0.03 }xmol/L, 20.5 -- 1.7 ~mol /L ,  and 
20.8 _ 1.7 Ixmol/L, respectively. They were compa- 
rable with those of the patients before the operation. 
At 14 days after operation, the plasma NO 3- and 
NO x levels in the femoral artery increased signifi- 
cantly to 42.8 _+ 5.6 txmol/L and 43.4 __ 5.6 
~mol/L ,  whereas the plasma NO 2- level (0.5 _ 
0.05 Ixmol/L) was not significantly different from 
that before the operation (Fig. 1). 
DISCUSSION 
EDRF-NO, which is synthesized from L-arginine 
by NO synthase, 2,1sA9 is not only a vasodilator but 
also a potent inhibitor of  platelet aggregation 3,2°,21 
and a modulator of vascular muscle cell mitogenesis 
and proliferation. 22EDRF-NO mediates these phys- 
iologic effects by an elevation of  intracellular cyclic 
guanosine monophosphate. 23 
NO is supposed to be degraded into nitrite 
(NO2-) and nitrate (NO3-) ions. 15 Because the sur- 
face area of endothelial cells in blood vessels is sup- 
posed to be large and faces the bloodstream, most 
NO x are thus most likely of  endothelial origin. If  the 
intake of the extrinsic NO were constant in a popu- 
lation without infectious diseases, the plasma con- 
centrations of NO x may thus reflect the amount of  
NO production from the endothelial cells. 24 
The present study demonstrated the NO x level in 
the control subjects without ASO to be significantly 
higher than that of patients who have ASO. In addi- 
tion, at 14 days after operation the plasma NO x level 
in the femoral artery also increased significantly with 
an improvement in the blood flow. Concerning the 
relationship between the chronic increase in the 
blood flow and EDRF-NO, Miller et al. 12,25 reported 
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Fig. 1. NO x (NO 2- + NO3- ) level changes in femoral artery before and after operation. In 
control (healthy) individuals, the plasma NO x level in femoral artery was 46.0 -+ 10.9 ~mol/L. 
This value was significantly higher than that of patients with ASO before operation. Before 
operation and at i hour after operation i  patients with ASO, plasma NOx was comparable. At 
14 days after operation, plasma NOx level in femoral artery increased significantly to 43.4 + 5.6 
ixmol/L, and this finding was comparable with that of control group. A, Healthy individuals; B, 
before operation i  patients with ASO; C, 1 hour after operation i  patients with ASO; D, 14 
days after operation i  patients with ASO. "Significant difference (p < 0.05) between A and B; 
Usignificant difference (p < 0.05) between A and C; Csignificant difference (p < 0.05) between B
and D; dsignificant difference (p < 0.05) between C and D. 
that chronic increases in the blood flow in canine 
femoral arteries enhanced endothelium-dependent 
relaxations to acetylcholine. They also reported that 
chronic increases in the blood flow selectively en- 
hanced the receptor-mediated r lease of EDRF. 25 In 
contrast, we recently reported that a chronic decrease 
in the blood flow impaired the endothelium-depen- 
dent responses in the canine femoral artery. 14 The 
endothelium-dependent r laxation can thus be mod- 
ulated by a chronic increase in blood flow. The 
mechanism underlying this modulation may be the 
shear stress-induced regulation of  endothelial cell 
NO synthase mRNA expression. 26 In the present 
study, the enhancement of NO production of  the 
peripheral arteries may therefore be caused by an 
improvement of  the blood flow in the peripheral 
arteries by an arterial reconstruction i the patients 
with ASO. 
Previous tudies have demonstrated that such he- 
modynamic factors as a low flow velocity and low 
shear stress result in the progression of late graft 
failure because ofintimal thickening. 27-31 Our recent 
experiments demonstrated animpairment of  the en- 
dothelium-dependent relaxations caused by adeno- 
sine diphosphate and thrombin in the abnormal 
f lowY Onohara et al. 33 also reported a dysfunction 
Of the cndothelium under an abnormal flow using 
the same poor runoff model. Under abnormal flow 
conditions characterized by a low shear stress varia- 
tion, the production of prostacyclin in the canine 
vein graft was lower than that in normal flow condi- 
tions. The dysfunction of the endothelium in terms 
of the decreased production of EDRF as well as 
decreased prostacyclin production under abnormal 
flow conditions may thus increase platelet aggrega- 
tion and eventually facilitate the development of pe- 
ripheral arterial occlusive disease and eventually re- 
sult in late graft failure. 
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In contrast, several reports have suggested that 
enhanced EDRF-NO production reduces the degree 
of intimal thickening in vein grafts. Eicosapentanoic 
acid reduced the intimal thickening of  autogenous 
vein grafts and enhanced the activity of EDRF- 
NO. s4 The administration of the NO precursor L- 
arginine has been shown to reverse the defects in NO 
activity and also reduce the development of prolifer- 
ative atherosclerotic lesions, ss Tarry and Makhoul s6 
demonstrated that L-arginine supplementation en- 
hanced NO production at the site of vascular healing 
and may thus reduce intimal hyperplasia after balloon 
angioplasty. In addition, in rabbit vein grafts, L- 
arginine reduced experimental vein graft intimal hy- 
perplasia? 7 A relationship may therefore exist be- 
tween NO and intimal thickening in vein grafts? 8-~° 
Currently, the generally excellent early and late re- 
sults of direct aortoiliofemoral reconstructions can 
be anticipated and are, in fact, achievable at highly 
acceptable patient morbidity and mortality rates. A 
consensus of several arge series support this finding, 
thus indicating that it is reasonable to expect an 
approximately 85% to 90% graft patency rate at 5 
years and a 70% to 75% rate at 10 years. 4a,42 There- 
fore, the enhancement of NO after arterial recon- 
struction in patients with aortoiliac occlusive disease 
is one of many possible mechanisms for maintaining 
the patency of the bypass graft or native artery. 
However, the current study focused only on the 
plasma NO levels taken from the femoral artery. To 
clarify the further possible role of NO, detailed fu- 
ture work, such as on regional variation of plasma 
NO obtained from different arteries, needs to be 
carried out. 
The major findings of the present study are that 
(1) in patients with ASO the plasma level of NO is 
significantly lower than that in healthy individuals; 
and (2) the enhancement of NO production inpa- 
tients with ASO after arterial reconstruction, which 
may be a result of the increased blood flow in the 
peripheral artery. This enhancement of the NO pro- 
duction may therefore help in maintaining the pa- 
tency of the bypass graft or native artery after arterial 
reconstruction. 
We thank Mr. Brian Qninn for reading the manu- 
script and providing helpful comments. 
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